Xenon Pharmaceuticals Inc.
XENE
$55.00
-$0.78-1.40%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | 0.00 | -- | -- | 7.50M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | 0.00 | -- | -- | 7.50M |
| Cost of Revenue | 88.51M | 87.70M | 77.05M | 74.99M | 61.20M |
| Gross Profit | -88.51M | -87.70M | -77.05M | -74.99M | -53.70M |
| SG&A Expenses | 23.82M | 22.07M | 19.28M | 19.24M | 19.04M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 112.33M | 109.77M | 96.34M | 94.23M | 80.24M |
| Operating Income | -112.33M | -109.77M | -96.34M | -94.23M | -72.74M |
| Income Before Tax | -104.87M | -104.72M | -90.22M | -85.33M | -64.62M |
| Income Tax Expenses | -2.57M | 538.00K | 677.00K | -626.00K | 427.00K |
| Earnings from Continuing Operations | -102.30M | -105.26M | -90.90M | -84.71M | -65.05M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -102.30M | -105.26M | -90.90M | -84.71M | -65.05M |
| EBIT | -112.33M | -109.77M | -96.34M | -94.23M | -72.74M |
| EBITDA | -111.74M | -109.16M | -95.70M | -93.60M | -72.08M |
| EPS Basic | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 |
| Normalized Basic EPS | -0.75 | -0.82 | -0.71 | -0.68 | -0.51 |
| EPS Diluted | -1.17 | -1.31 | -1.15 | -1.07 | -0.83 |
| Normalized Diluted EPS | -0.75 | -0.82 | -0.71 | -0.68 | -0.51 |
| Average Basic Shares Outstanding | 87.35M | 80.13M | 79.25M | 78.95M | 78.69M |
| Average Diluted Shares Outstanding | 87.35M | 80.13M | 79.25M | 78.95M | 78.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |